ZTS
$121.68
Zoetis Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the Uni...
Recent News
Zoetis Cuts Guidance As Librela Safety Questions Test Growth Story
Zoetis (NYSE:ZTS) reduced its full year guidance after raising safety concerns around its osteoarthritis drug Librela. Management said it intends to address questions on Librela with science based evidence on safety and efficacy. The update has drawn attention because Librela is an important product within Zoetis's animal health portfolio. For investors watching Zoetis at a share price of $118.15, the guidance cut tied to Librela comes on top of a weak longer term share performance. The...
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
Zoetis (ZTS) closed the most recent trading day at $118.15, moving +2.19% from the previous trading session.
Is Zoetis Inc. (ZTS) A Good Stock To Buy Now?
Is ZTS a good stock to buy now? We came across a bullish thesis on Zoetis Inc. on Rebound Capital’s Substack. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $131.10 as of February 27th. ZTS’s trailing and forward P/E were 21.78 and 19.08 respectively according to Yahoo Finance. Zoetis […]
2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 3.8% over the past six months, almost identical to the S&P 500.
Zoetis (ZTS) Loses 8.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Zoetis (ZTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.